These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 31134657)

  • 1. Effects of Ketoconazole, a CYP4F2 Inhibitor, and CYP4F2*3 Genetic Polymorphism on Pharmacokinetics of Vitamin K
    Park JW; Kim KA; Park JY
    J Clin Pharmacol; 2019 Nov; 59(11):1453-1461. PubMed ID: 31134657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant.
    McDonald MG; Rieder MJ; Nakano M; Hsia CK; Rettie AE
    Mol Pharmacol; 2009 Jun; 75(6):1337-46. PubMed ID: 19297519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of CYP4F2 polymorphism on response to warfarin during induction phase: a prospective, open-label, observational cohort study.
    Bejarano-Achache I; Levy L; Mlynarsky L; Bialer M; Muszkat M; Caraco Y
    Clin Ther; 2012 Apr; 34(4):811-23. PubMed ID: 22417713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between CYP4F2 genotype and circulating plasma vitamin K concentration in children on chronic warfarin therapy: Possible long-term implications for bone development and vascular health.
    Kampouraki E; Avery PJ; Biss T; Kamali F
    Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28521079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of incorporating ABCB1 and CYP4F2 polymorphisms in a pharmacogenetics-guided warfarin dosing algorithm for the Brazilian population.
    Tavares LC; Duarte NE; Marcatto LR; Soares RAG; Krieger JE; Pereira AC; Santos PCJL
    Eur J Clin Pharmacol; 2018 Dec; 74(12):1555-1566. PubMed ID: 30051215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of CYP2C9, VKORC1, and CYP4F2 polymorphisms on warfarin maintenance dose in children aged less than 18 years: a protocol for systematic review and meta-analysis.
    Takeuchi M; Kobayashi T; Brandão LR; Ito S
    Syst Rev; 2016 Jun; 5(1):105. PubMed ID: 27334984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ketoconazole increases fingolimod blood levels in a drug interaction via CYP4F2 inhibition.
    Kovarik JM; Dole K; Riviere GJ; Pommier F; Maton S; Jin Y; Lasseter KC; Schmouder RL
    J Clin Pharmacol; 2009 Feb; 49(2):212-8. PubMed ID: 19118083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Computational analysis of missense variant CYP4F2*3 (V433M) in association with human CYP4F2 dysfunction: a functional and structural impact.
    Farajzadeh-Dehkordi M; Mafakher L; Samiee-Rad F; Rahmani B
    BMC Mol Cell Biol; 2023 May; 24(1):17. PubMed ID: 37161313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional Characterization of 29 Cytochrome P450 4F2 Variants Identified in a Population of 8380 Japanese Subjects and Assessment of Arachidonic Acid
    Sato Y; Hishinuma E; Yamazaki S; Ueda A; Kumondai M; Saito S; Tadaka S; Kinoshita K; Nakayoshi T; Oda A; Maekawa M; Mano N; Hirasawa N; Hiratsuka M
    Drug Metab Dispos; 2023 Dec; 51(12):1561-1568. PubMed ID: 37775333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic polymorphisms of patients on stable warfarin maintenance therapy in a Ghanaian population.
    Kudzi W; Ahorhorlu SY; Dzudzor B; Olayemi E; Nartey ET; Asmah RH
    BMC Res Notes; 2016 Dec; 9(1):507. PubMed ID: 27938396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of CYP4F2 genetic polymorphisms and haplotypes on clinical outcomes in patients initiated on warfarin therapy.
    Zhang JE; Jorgensen AL; Alfirevic A; Williamson PR; Toh CH; Park BK; Pirmohamed M
    Pharmacogenet Genomics; 2009 Oct; 19(10):781-9. PubMed ID: 19741565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of genetic factors (CYP2C9, VKORC1 and CYP4F2) on warfarin dose requirement in the Turkish population.
    Özer M; Demirci Y; Hizel C; Sarikaya S; Karalti İ; Kaspar Ç; Alpan S; Genç E
    Basic Clin Pharmacol Toxicol; 2013 Mar; 112(3):209-14. PubMed ID: 23061746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic Evaluation of the Interactions of Amenamevir (ASP2151) with Ketoconazole, Rifampicin, Midazolam, and Warfarin in Healthy Adults.
    Kusawake T; den Adel M; Groenendaal-van de Meent D; Garcia-Hernandez A; Takada A; Kato K; Ohtsu Y; Katashima M
    Adv Ther; 2017 Nov; 34(11):2466-2480. PubMed ID: 29076107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrating interacting drugs and genetic variations to improve the predictability of warfarin maintenance dose in Chinese patients.
    Zhong SL; Yu XY; Liu Y; Xu D; Mai LP; Tan HH; Lin QX; Yang M; Lin SG
    Pharmacogenet Genomics; 2012 Mar; 22(3):176-82. PubMed ID: 22198820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Verification of accuracy of warfarin stable dose prediction models in Shandong population].
    Ge Y; Qu F; Wang S; Guo X; Wang C; Liu S; Ma A; Jiang X; Tan K
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2020 Apr; 37(4):401-404. PubMed ID: 32219822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of the
    Sun X; Yu WY; Ma WL; Huang LH; Yang GP
    Biomed Rep; 2016 Apr; 4(4):498-506. PubMed ID: 27073641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Genetic Variability in the
    Zhang JE; Klein K; Jorgensen AL; Francis B; Alfirevic A; Bourgeois S; Deloukas P; Zanger UM; Pirmohamed M
    Front Pharmacol; 2017; 8():323. PubMed ID: 28620303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic polymorphism of cytochrome P450 4F2, vitamin E level and histological response in adults and children with nonalcoholic fatty liver disease who participated in PIVENS and TONIC clinical trials.
    Athinarayanan S; Wei R; Zhang M; Bai S; Traber MG; Yates K; Cummings OW; Molleston J; Liu W; Chalasani N
    PLoS One; 2014; 9(4):e95366. PubMed ID: 24759732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A regression model to predict warfarin dose from clinical variables and polymorphisms in CYP2C9, CYP4F2, and VKORC1: Derivation in a sample with predominantly a history of venous thromboembolism.
    Wells PS; Majeed H; Kassem S; Langlois N; Gin B; Clermont J; Taljaard M
    Thromb Res; 2010 Jun; 125(6):e259-64. PubMed ID: 20421126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of UDP-Glucuronosyltransferase Polymorphisms on Stable Warfarin Doses in Patients with Mechanical Cardiac Valves.
    An SH; Chang BC; Lee KE; Gwak HS
    Cardiovasc Ther; 2015 Dec; 33(6):324-8. PubMed ID: 26223945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.